Ubs Group Ag Tango Therapeutics, Inc. Transaction History
Ubs Group Ag
- $400 Billion
- Q2 2024
A detailed history of Ubs Group Ag transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 151,315 shares of TNGX stock, worth $895,784. This represents 0.0% of its overall portfolio holdings.
Number of Shares
151,315
Previous 158,226
4.37%
Holding current value
$895,784
Previous $1.26 Million
3.34%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding TNGX
# of Institutions
121Shares Held
89.1MCall Options Held
2.6KPut Options Held
1K-
Trv Gp Iv, LLC Boston, MA19.2MShares$114 Million81.48% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA13.3MShares$78.9 Million4.04% of portfolio
-
Boxer Capital, LLC San Diego, CA8.2MShares$48.5 Million3.91% of portfolio
-
Nextech Invest Ag5.53MShares$32.8 Million8.96% of portfolio
-
Southpoint Capital Advisors LP New York, NY5.28MShares$31.2 Million1.32% of portfolio
About Tango Therapeutics, Inc.
- Ticker TNGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 88,067,296
- Market Cap $521M
- Description
- Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...